SIGLEC1 and myeloid sarcoma: The study by Malhotra et al.14 focussed on untreated MS patients and identified modest increases in SIGLEC1 expression in MS patients (approximately twofold increase of MFI between MS patients and HC) and especially those with progressive disease.